A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Trial Profile

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs Ruxolitinib deuterated (Primary)
  • Indications Alopecia areata
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Concert Pharmaceuticals
  • Most Recent Events

    • 12 Feb 2018 According to a Concert Pharmaceuticals media release, the company expects to report topline data in the fourth quarter of 2018.
    • 12 Feb 2018 According to a Concert Pharmaceuticals media release, An independent Data Monitoring Committee (DMC) conducted an interim safety data review of the first cohort. Based on this review, the DMC provided its recommendation to continue with the current cohort and to initiate dosing of the second cohort.
    • 12 Feb 2018 According to a Concert Pharmaceuticals media release, the company has initiated enrollment for the second cohort of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top